The notable: Bcr-abl is a single translocated change in chrinic myelogenous leukemia. The target drug (imatinib, gleevec) controls the mutation, and the disease. Gi stromal tumors, gist, has c-kit managed by the same drug, but resistance occurs. Common cancers are poly-mutated genes. Even brca-1 =2 mutation convey risk in breast and ovarian cancer, not just one gene= cancer.
Answered 6/9/2012
5.8k views
4 doctors weighed in across 2 answers
A doctor has provided 1 answer
2 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question